Fundz

Ncardia Secures $60+ Million To Enhance And Expand Leading Ipsc Offerings

PRIVATENov 16, 2021

Amount Raised

$60 Million

Round Type

Funding Round

GosseliesBiotechnologyHealth CareScience And Engineering

Description

Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide. Kiniciti is backed by Welsh, Carson, Anderson & Stowe (WCAS), a leading private equity firm investing in healthcare and technology, and Biospring Partners. The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to commercial production.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Ncardia that raised within 45 days of this round, from Fundz verified event records.

  • Trait Biosciences Inc. raised an undisclosed amount (Series A) on December 30, 2021.
  • TandemAI raised $25M (Seed) on December 22, 2021.
  • Appili Therapeutics Inc. raised an undisclosed amount (Funding Round) on December 22, 2021.
  • 20n Bio raised $3.3M (Seed) on December 17, 2021.
  • Specific Biologics raised an undisclosed amount (Seed) on December 16, 2021.
  • Mythic Therapeutics raised an undisclosed amount (Series B) on December 15, 2021.

Who to call at Ncardia, and when

A new round usually means Ncardia is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ncardia raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ncardia, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ncardia. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ncardia

Location

Gosselies, Hainaut, Belgium

About

Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. The company’s goal is to enable biopharmaceutical companies in drug discovery and cell therapy to accelerate their development processes through the integration of human iPSC technologies. For more information, visit ncardia.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ncardia raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Ncardia's next move

See what Strategic adds

Ncardia raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.